Disease modifying potential of glatiramer acetate in huntington's disease

Journal of Huntington's Disease

Volumn 3, Issue 3, 2014, Pages 311-316

  Corey Bloom, Jody ^a   Jia, Haiqun ^b   Aikin, Alaina M ^b   Thomas, Elizabeth A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

BDNF; copaxone; Glatiramer acetate; jumping; neurodegenerative; striatum

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUNTINGTON CHOREA; HYPERACTIVITY; IMMUNOCOMPETENT CELL; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; TRANSGENIC MOUSE; TREATMENT OUTCOME; ANIMAL; BRAIN; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; FEASIBILITY STUDY; HUMAN; HUNTINGTON DISEASE; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; GLATIRAMER ACETATE; HUMANS; HUNTINGTON DISEASE; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; TREATMENT OUTCOME;

EID: 84930189896     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-140110     Document Type: Article

References (44)

1. Huntington's Disease Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993;72:971-83.
2. Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010;8:331-73.
3. Greenberg ME, Xu B, Lu B, Hempstead BL. New insights in the biology of BDNF synthesis and release: Implications in CNS function. J Neurosci. 2009;29:12764-7.
4. Lu B. BDNF and activity-dependent synaptic modulation. Learn Mem. 2003;10:86-98.
5. Patapoutian A, Reichardt LF. Trk receptors: Mediators of neurotrophin action. Curr Opin Neurobiol. 2001;11:272-80.
6. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, Lindsay RM, Wiegand SJ. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature. 1997;389:856-60.
7. Ma B, Savas JN, ChaoMV, Tanese N. Quantitative analysis of BDNF/TrkB protein and mRNA in cortical and striatal neurons using alpha-tubulin as a normalization factor. Cytometry A. 2012;81.
8. Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. Embo J. 1990;9:2459-64.
9. Runne H, Regulier E, Kuhn A, Zala D, Gokce O, Perrin V, Sick B, Aebischer P, Deglon N, Luthi-Carter R. Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. J Neurosci. 2008;28:9723-31.
10. Tang B, Di Lena P, Schaffer L, Head SR, Baldi P, Thomas EA. Genome-wide identification of Bcl11b gene targets reveals role in brain-derived neurotrophic factor signaling. PLoS ONE. 2011;6:e23691.
11. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: Implications for the therapy of multiple sclerosis. Neurol Sci. 2006;27(Suppl 1):S1-7.
12. Gharami K, Xie Y, An JJ, Tonegawa S, Xu B. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J Neurochem. 2008;105:369-79.
13. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 2001;293: 493-8.
14. Xie Y, Hayden MR, Xu B. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J Neurosci. 2010;30:14708-14718.
15. Zuccato C, Marullo M, Conforti P, MacDonald ME, Tartari M, Cattaneo E. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol. 2008;18:225-38.
16. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, Cataudella T, Leavitt BR, Hayden MR, Timmusk T, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet. 2003;35:76-83.
17. Ferrer I, Goutan E, Marin C, Rey MJ, Ribalta T. Brainderived neurotrophic factor in Huntington disease. Brain Res. 2000;866:257-61.
18. DuanW, Guo Z, Jiang H,Ware M, Li XJ, MattsonMP. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A. 2003;100: 2911-6.
19. ZhangY, Li M, Drozda M, Chen M, Ren S, Mejia SanchezRO, Leavitt BR, Cattaneo E, Ferrante RJ, HaydenMR,et al. Depletion of wild-type huntingtin in mouse models of neurologic diseases. J Neurochem. 2003;87:101-6.
20. Giampa C, Montagna E, Dato C, Melone MA, Bernardi G, Fusco FR. Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease. PLoS ONE. 2013;8:e64037.
21. Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Martin-Ibanez R, Munoz MT, Mengod G, Ernfors P, Alberch J. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci. 2004;24:7727-39.
22. Apostol BL, Simmons DA, Zuccato C, Illes K, Pallos J, Casale M, Conforti P, Ramos C, Roarke M, Kathuria S, et al. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restoresBDNFlevels in R6/2 mice. Mol Cell Neurosci. 2008;39:8-20.
23. Dey ND, Bombard MC, Roland BP, Davidson S, Lu M, Rossignol J, Sandstrom MI, Skeel RL, Lescaudron L, Dunbar GL. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease. Behav Brain Res. 2010;214:193-200.
24. Kells AP, Fong DM, Dragunow M, During MJ, Young D, Connor B. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther. 2004;9:682-8.
25. Iwasaki Y, Negishi T, Inoue M, Tashiro T, Tabira T, Kimura N. Sendai virus vector-mediated brain-derived neurotrophic factor expression ameliorates memory deficits and synaptic degeneration in a transgenic mouse model of Alzheimer's disease. J Neurosci Res. 2012;90:981-9.
26. Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011;10:209-19.
27. Nilsson P, Iwata N, Muramatsu S, Tjernberg LO,Winblad B, Saido TC. Gene therapy in Alzheimer's disease-potential for disease modification. J Cell Mol Med. 2010;14:741-57.
28. Neuhaus O, Farina C,Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology. 2001;56:702-8.
29. Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A. 2003;100:14157-62.
30. Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1-and 2-type cell lines produce BDNF: Implications for multiple sclerosis therapy. Brain-Derived Neurotrophic Factor. Brain. 2002;125:2381-91.
31. Chen M, Valenzuela RM, Dhib-Jalbut S. Glatiramer acetatereactive T cells produce brain-derived neurotrophic factor. J Neurol Sci. 2003;215:37-44.
32. Blanco Y, Moral EA, Costa M, Gomez-Choco M, Torres-Peraza JF, Alonso-Magdalena L, Alberch J, Jaraquemada D, Arbizu T, Graus F, et al. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: A longitudinal study. Neurosci Lett. 2006;406:270-5.
33. Song F, Bandara M, Deol H, Loeb JA, Benjamins J, Lisak RP. Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: Differential expression of neurotrophic and gliotrophic factors. J Neuroimmunol. 2013;262:11-18.
34. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, Cattaneo E, MacDonald ME. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet. 2000;9:2799-809.
35. Aharoni R, Eilam R, Domev H, Labunskay G, Sela M, Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A. 2005;102:19045-19050.
36. Schilling G, Coonfield ML, Ross CA, Borchelt DR. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett. 2001;315:149-53.
37. Schilling G, Jinnah HA, Gonzales V, Coonfield ML, Kim Y, Wood JD, Price DL, Li XJ, Jenkins N, Copeland N, et al. Distinct behavioral and neuropathological abnormalities in transgenic mouse models of HD and DRPLA. Neurobiol Dis. 2001;8:405-418.
38. Jia H, Kast RJ, Steffan JS, Thomas EA. Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: Implications for the ubiquitinproteasomal and autophagy systems. Hum Mol Genet. 2012; 21(24):5280-93.
39. Andre VM, Cepeda C, Fisher YE, Huynh M, Bardakjian N, Singh S,YangXW, Levine MS. Differential electrophysiological changes in striatal output neurons in Huntington's disease. J Neurosci. 2011;31:1170-82.
40. Bolivar VJ, Manley K, Messer A. Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice. Brain Res. 2004;1005:29-35.
41. Mochel F, Durant B, Durr A, Schiffmann R. Altered dopamine and serotonin metabolism in motorically asymptomatic R6/2 mice. PLoS ONE. 2011;6:e18336.
42. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9:203-14.
43. Hines RM, Wu L, Hines DJ, Steenland H, Mansour S, Dahlhaus R, Singaraja RR, Cao X, Sammler E, Hormuzdi SG, et al. Synaptic imbalance, stereotypies, and impaired social interactions in mice with altered neuroligin 2 expression. J Neurosci. 2008;28:6055-6067.
44. Johnson KP. Glatiramer acetate for treatment of relapsingremitting multiple sclerosis. Expert Rev Neurother. 2012;12: 371-84.